DexCom insider plans sale of 1,012 common shares

DexCom, Inc. insider Bridgette P. Heller filed a notice of proposed sale of 1,012 shares of common stock of DXCM, to be sold through Fidelity Brokerage Services LLC on or after August 12, 2026 on NASDAQ.

Rhea-AI Filing Summary

DexCom, Inc. insider Bridgette P. Heller filed a notice of proposed sale of 1,012 shares of common stock of DXCM, to be sold through Fidelity Brokerage Services LLC on or after August 12, 2026 on NASDAQ. The shares were acquired via restricted stock vesting from the issuer as compensation on September 29, 2021. Heller also reported having sold 1,012 common shares during the past three months on May 12, 2026 for $60,730.12.

Key Figures

Proposed shares to be sold: 1,012 shares Aggregate market value of proposed sale: $89,349.48 Prior 3-month sale shares: 1,012 shares +2 more

5 metrics

Proposed shares to be sold 1,012 shares Common stock sale through Fidelity on or after August 12, 2026

Aggregate market value of proposed sale $89,349.48 Value of 1,012 DexCom common shares planned for sale

Prior 3-month sale shares 1,012 shares Common stock sold on May 12, 2026

Proceeds from prior sale $60,730.12 Total proceeds from 1,012 shares sold on May 12, 2026

Acquisition date of shares September 29, 2021 Restricted stock vesting as compensation from issuer

Key Terms

Form 144, Restricted Stock Vesting, Compensation, Securities Sold During The Past 3 Months

4 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Vesting financial

"Common | 09/29/2021 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Compensation financial

"1012 | 09/29/2021 | Compensation"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does DexCom (DXCM) Form 144 filed by Bridgette P. Heller disclose?

The Form 144 discloses that Bridgette P. Heller intends to sell 1,012 shares of DexCom common stock through Fidelity on or after August 12, 2026, and that these shares came from restricted stock vesting awarded as compensation.

How many DexCom (DXCM) shares are proposed to be sold in this Form 144?

The filing reports a proposed sale of 1,012 shares of DexCom common stock. These shares are to be sold through Fidelity Brokerage Services LLC and are listed for trading on NASDAQ starting on or after August 12, 2026.

What is the aggregate market value of the DexCom (DXCM) shares in the proposed Form 144 sale?

The proposed sale covers shares with an aggregate market value of $89,349.48. This value is associated with the 1,012 DexCom common shares Heller plans to sell through Fidelity Brokerage Services LLC on or after August 12, 2026.

How and when did Bridgette P. Heller acquire the DexCom (DXCM) shares listed in the Form 144?

The filing states the shares were acquired via Restricted Stock Vesting from the issuer as compensation on September 29, 2021. This indicates the 1,012 common shares originated from an equity compensation award rather than an open-market purchase.

What DexCom (DXCM) stock sales has Bridgette P. Heller made in the past three months?

The Form 144 notes that Heller sold 1,012 shares of DexCom common stock on May 12, 2026 for total proceeds of $60,730.12. This prior transaction is listed in the section covering securities sold during the past 3 months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2026 - 10:22 AM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001485616
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	DEXCOM INC
SEC File Number	000-51222
Address of Issuer	6340 SEQUENCE DRIVE SAN DIEGO CALIFORNIA 92121
Phone	8582000200
Name of Person for Whose Account the Securities are To Be Sold	Heller Bridgette P
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1012	89349.48	377360765	08/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/29/2021	Restricted Stock Vesting	Issuer			1012	09/29/2021	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Bridgette P. Heller 6340 Sequence Drive San Diego CA 92121	Common	05/12/2026	1012	60730.12

144: Remarks and Signature

Remarks
Date of Notice	08/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Gary Redman, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Bridgette P. Heller
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)